Subscribe for the newsletter
Sign in
Articles
Expert Interviews
Roundtable
Press Releases
Videos
The Road To Series
Market Research
Directory
More
Discovery
Small Molecules
Biologics
Advanced Therapies
Manufacturing
Supply Chain
Clinical Trials
Technologies
Financing
Array BioPharma
Sort By
Newest First
1 / 1
M&A
Pfizer Completes Acquisition of Array Biopharma
Pfizer
PR-M07-19-NI-080
Jul 31, 2019
Clinical Results
Positive Results for Colon Cancer Drug Drove Pfizer’s Purchase of Array BioPharma
Cynthia A. Challener, Ph.D.
Pharma's Almanac
PAO-M07-19-NI-017
Jul 16, 2019
M&A
Pfizer Acquires Array BioPharma for $11.4 Billion
Nice Insight
PAO-M06-19-NI-018
Jun 21, 2019
M&A
Pfizer to Acquire Array BioPharma
Array BioPharma
PR-M06-19-NI-027
Jun 19, 2019
Endpoint
Array Biopharma Announces Braftovi + Mektovi + Cetuximab Meet Primary Endpoints in Metastatic Colorectal Cancer
Array BioPharma
PR-M05-19-NI-069
May 23, 2019
Vaccines
GSK Ships 2018-19 Seasonal Influenza Vaccines for US Market
GSK Contract Manufacturing
PR-M08-18-NI-110
Aug 29, 2018
FDA Designation
Array BioPharma Receives FDA Breakthrough Therapy Designation for BRAFTOVI™ in combination with MEKTOVI® and cetuximab for BRAFV600E-mutant Metastatic Colorectal Cancer
Array BioPharma
PR-M08-18-NI-070
Aug 16, 2018
Clinical Data
BRAFTOVI™ (encorafenib) + MEKTOVI® (binimetinib) Receives Positive CHMP Opinion for Advanced BRAF-mutant Melanoma
Array BioPharma
PR-M08-18-NI-010
Aug 02, 2018
Clinical Data
Array BioPharma Announces a 62% Observed Overall Survival at One Year from the Phase 3 BEACON CRC Safety Lead-In
Array BioPharma
PR-M06-18-NI-086
Jun 26, 2018
Clinical Trials
Array BioPharma to Present Overall Survival Results from the Phase 3 LUNGevity Takes Step Forward in Clinical Trial Eligibility Reform for Lung Cancer Patients
LUNGevity Foundation
PR-M06-18-NI-062
Jun 20, 2018
Clinical Data
Pierre Fabre and Array BioPharma Announce COLUMBUS Phase 3 Study Overall Survival Results in BRAF-Mutant Melanoma Will Be Presented at 2018 ASCO Annual Meeting
Pierre Fabre
PR-M05-18-NI-076
May 21, 2018
Clinical Trials
Encorafenib and Binimetinib Combination Treatment Demonstrates 33.6 Month Median Overall Survival (OS) in Patients with BRAF-Mutant Melanoma
Array BioPharma
PR-M02-18-NI-043
Feb 13, 2018
Oncology
Combination of Encorafenib, Binimetinib and Cetuximab Demonstrated an 8 Month Median Progression-Free Survival
PR-M01-18-NI-081
Jan 25, 2018
Drug Development
Array BioPharma Forms New Subsidiary Yarra Therapeutics
Nice Insight
PAO-M01-18-NI-007
Jan 04, 2018
Immuno-Oncology
Bristol-Meyers Squibb, Array BioPharma Enter Strategic Collaboration
Cynthia A. Challener, Ph.D.
Pharma's Almanac
PAO-M05-17-NI-036
May 31, 2017
1 / 1
